Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rabies Vaccine Responsiveness After CAR-T
NCT04410900Phase 1Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Aug 2020
- Primary completion
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of rabies virus inactivated antigen, B in rabies (3 arms), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Proportion of participants with positive vaccine response. Started Aug 2020; status: completed.
02
Drugs
rabies virus inactivated antigen, B
03
Conditions
rabies
Beyond the preview
Go deeper on NCT04410900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04410900.